Please assess the completion status of the following clinical trial:

Trial Title: Detrol Long Acting (LA) vs Estrace Vaginal Cream for the Treatment of Overactive Bladder Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Irritative voiding symptoms to include sensory urgency, frequency, urge incontinence, nocturia~* Postmenopausal women with a prior oophorectomy or 1 year from last menstrual period~* Women age 40-90~* Women with hysterectomy with preserved ovaries must be age 55 or greater or have a documented follicle-stimulating hormone (FSH)\>40 to ensure post-menopausal status~* Community dwelling~* Ambulatory~* Ability to participate in a 12 month study~Exclusion Criteria:~* Post-void residual volume\>150ml~* Glaucoma without ophthalmologist clearance~* Hormone replacement therapy in the past 6 months~* Current anticholinergic treatment~* Breast cancer~* Impaired mental status~* Undiagnosed vaginal bleeding in the past 12 months~* Endometrial thickness on pelvic ultrasound \>5mm~* History of thromboembolic event~* Gynecologic cancer~* Untreated urinary tract infection (would be eligible after treatment)~* Stage III pelvic organ prolapse or greater~* Recent diuretic medication changes (one month from change)~* Neurologic condition affecting bladder function (Multiple Sclerosis, Parkinsons, spinal cord injury, spina bifida)~* Congestive heart failure~* Prior pelvic irradiation~* Interstitial cystitis

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- Extended Release Tolterodine LA (Type: ACTIVE_COMPARATOR): An anti-muscarinic drug that is used for symptomatic treatment of urinary incontinence.
- Intra Vaginal Estradiol Cream (Type: ACTIVE_COMPARATOR): For topical application to the vaginal area to treat symptoms of urgency or irritation with urination.

Based on this trial design, predict the completion outcome and termination type (if applicable).